The high incidence of tetracycline resistance among clinically important microorganisms imposes a severe limitation on the use of tetracyclines in the treatment of bacterial infections. Two major mechanisms of tetracycline resistance exist: tetracycline effiux, active pumping out of the tetracycline decreasing the intracellular concentration, and ribosomal protection, by which the protein synthesis machinery is rendered resistant to inhibition of protein synthesis (1, 2, 10) . Resistance mediated via tet(M) is of the latter class. The exact mechanism by which TetM functions is unknown. The TetM protein shares strong homology with and has many of the attributes of elongation factor G, such as the ability to hydrolyze GTP in the presence of ribosomes (2) . Whether this homology is directly related to TetM's ability to permit protein synthesis in the presence of tetracycline is unclear. However, it has been demonstrated that ribosomes isolated from tet(M) cells are resistant to inhibition of protein synthesis by the currently marketed tetracycline compounds (1) (2) (3) .
A new generation of tetracycline compounds, the glycylcyclines, including DMG-MINO (N,N-dimethylglycylamido minocycline) and DMG-DMDOT (N,N-dimethylglycylamido 6-demethyl-6-deoxytetracycline) have been identified (11) . The glycylcyclines are capable of inhibiting protein synthesis occurring on wild-type ribosomes. In addition, they are able to inhibit protein synthesis occurring on TetM-protected, tetracycline-resistant ribosomes. This is the first demonstration of a tetracycline compound that is able to inhibit protein synthesis occurring on TetM-protected ribosomes. Two methods have been used to demonstrate the ability of the glycylcyclines to specifically inhibit protein synthesis occurring on either tetracycline-sensitive, wild-type ribosomes, or tetracycline-resistant, TetM-protected ribosomes. The first is an in vitro protein synthesis system. The second is an in vivo assay for inhibition of macromolecular synthesis, assessing the incorporation of protein, DNA, or RNA precursors into macromolecules.
Inhibition of protein synthesis in vitro. The ability of the glycylcyclines to inhibit protein synthesis in vitro was demonstrated by using a DNA-directed protein synthesis system similar to that originally described by Zubay (12) . The system used in these studies was as described by Collins (6) . The assay utilized pUC119 as the DNA template. S30 extracts were prepared from Escherichia coli MRE600 (4) or the TetMexpressing strain MRE600(pAT182), in which pAT182 harbors the tet(M) gene from the streptococcal conjugative transposon TnlS45 (7) . Each reaction mixture contained 3.5 RI of lowmolecular-weight mix (6); 1.0 RIl of template plasmid (1 jig/Rl); All of the tetracycline and glycylcycline compounds tested were effective at inhibiting protein synthesis when the S30 extract used was prepared from the wild-type strain and contained tetracycline-sensitive ribosomes (Fig. 1A) . Tetracycline was slightly less effective at inhibiting protein synthesis with an IC50 (the concentration of compound needed to reduce the incorporation of [35S]methionine by 50%) of approximately 0.06 mg/ml. Minocycline and the two glycylcyclines exhibited IC50s of <0.03 mg/ml. However, when the S30 extract was prepared from the tetracycline-resistant strain and contained TetM-protected ribosomes, tetracycline and minocycline were significantly less effective at inhibiting protein synthesis (Fig. 1B) . The IC50s for tetracycline and minocycline were 0.25 and 0.12 mg/ml, respectively. In contrast, the two glycylcycline compounds, DMG-MINO and DMG-DMDOT, were highly effective at inhibiting protein synthesis occurring on TetM-protected ribosomes. The inhibition of incorporation of methionine was nearly identical to that seen when the tetracycline-sensitive ribosome S30 extract was used. Both glycylcycline compounds had IC50s of <0.03 mg/ml. The glycylcyclines were more than four-to eightfold better at inhibiting protein synthesis occurring on TetM-protected ribosomes than either tetracycline or minocycline. Unlike tetracycline and minocycline, DMG-MINO and DMG-DMDOT were equally effective at inhibiting protein synthesis in vitro whether sis, these compounds were tested for their effect on macromo-------lecular synthesis in vivo. E. coli MC4100 (5) or MC4100 * -'e -w | (pAT182) (7) cells were grown at 37°C on M63 glucose 1 minimal medium (8) 
